Therapix Biosciences Provides Update on Planned Merger With Destiny Biosciences Global Corp.
(WorldNews Health)

Therapix Biosciences Provides Update on Planned Merger With Destiny Biosciences Global Corp. TEL AVIV, Israel, Oct. 10, 2019/PRNewswire / -- Therapix Biosciences Ltd. (`Therapix` or the `Company`) (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today an update on its planned merger with Destiny Biosciences Global Corp. (`Destiny`). On July 23, 2019, Therapix announced the signing of a Letter of Intent for a proposed merger with Destiny. If completed, the transaction will create a combined company that focuses on Therapix`s proprietary IP and related technology, and assets pertaining to all clinical...